Skip to main content
Equibles
ANRO logo

ANRO · Alto Neuroscience, Inc.

Track ANRO — free

Use ANRO with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research ANRO.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$32.00 +0.32 (+1.01%) At close · Sep 11
Russell 2000 member Rebalance outlook locked
Market Cap
$1.25B
Shares
39.24M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$32.00 Open$32.00 Day$31.11–33.13 52W close$3.60–36.64 Avg vol 30d468K Short int3.8M · 9.8% float · 8.1d Short vol74% Last earningsMar 16, 2026 DataFeb 2024–Sep 2026 Filing10-Q · Aug 12

Up next

Next earnings call
Oct 17, 2026 Est · unconfirmed · in 5 wks
Latest filing: 10-Q
filed Aug 12, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
−$84.24M
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-5.5%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$227.55M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+58.1%
Year over year · more shares
Price change (1Y)
+789.9%
Trailing year
Short interest
9.8%
Latest settlement · 8.1 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Buy
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Strong Quant / Vol Very High
Market backdrop VIX 15.8 · calm Equity put/call 0.60
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +41%
above
Price vs 50-day avg +5%
above
RSI (14) 45
neutral
MACD trend Negative
52-week position 86%
near high
Momentum
relative strength
Very Strong
1-month return −1%
trailing
6-month return +49%
trailing
YTD return +80%
this year
Relative strength +31%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $30 › 200d $23 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.78% of float · ▲ +7.9% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
116 holders — near 2-yr high, broad support
Squeeze score 83
high risk · 0–100
Fundamentals
Strong
EPS growth +12%
Y/Y
Free cash flow $-51.8M
Balance sheet $159.7M
net cash
Quant / Vol
risk profile
Very High
Volatility 128%
annualized · 1-yr
Max drawdown −34%
past year
ATR 6.5%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Buy
1 · 2 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+41% Bullish
Price vs 50-day avg
+5% Bullish
RSI (14)
45 Neutral
MACD trend
Negative Bearish
52-week position
86% Bullish
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $30 › 200d $23 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +27 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
9.78% of float · ▲ +7.9% MoM · 8.1 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
116 holders — near 2-yr high, broad support
Price context
position in its 52-week range
Range low $4 Now $32 · 86% Range high $37
vs 200-day avg +41% vs 50-day avg +5%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ANRO
Alto Neuroscience, Inc.
this stock
$1.25B +79.8% — — 9.8%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $130.40B +13.7% +46.2% 30.0 1.8%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.67B +1.2% +20.8% 19.6 2.5%
ARGX
Argenx SE
 $61.60B +17.1% — — 2.0%
CSLLY
Csl Ltd
 $57.41B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
116
% held
75.4%
Net QoQ
+2.3M sh
Top holder
Alpha Wave Global, LP
Held Float
View
Held by Funds
Fund positions
86
View
Short & Settlement
Short Interest Rising
Shares short
3.8M
Days to cover
8.1d
Change
+280.3K sh
View
Short Volume
Short vol %
74%
As of
Sep 11, 2026
Short Total
View
Fails to Deliver
FTD shares
1.6K
Value
$46.1K
As of
Aug 11, 2026
View
Off-Exchange
Off-exchange %
35.9%
Week of
Aug 3, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-63.2M
EPS diluted
$-2.19
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 27, 2026
This year
15
View
Exempt Offerings
Offering
$50.0M
Filed
Oct 27, 2025
View
Earnings & Events
Earnings Calls Upcoming
Next call
Sep 14, 2026
Last call
Jun 3, 2026
View
Investor Relations
Latest news
Alto Neuroscience Announces Parti…
Published
Sep 9, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
ANRO -12.1% -0.9% +49.1% -9.6% +79.8%
SPY -1.2% -1.8% +17.8% -0.4% +12.1%
vs SPY -10.9% +0.8% +31.2% -9.2% +67.7%
Key facts CIK 1999480 CUSIP 02157Q109 13F (30d) 69 filings 69 filers Visit website Investor relations